| Autor: |
Ezra Y. Rosen, Helen H. Won, Youyun Zheng, Emiliano Cocco, Duygu Selcuklu, Yixiao Gong, Noah D. Friedman, Ino de Bruijn, Onur Sumer, Craig M. Bielski, Casey Savin, Caitlin Bourque, Christina Falcon, Nikeysha Clarke, Xiaohong Jing, Fanli Meng, Catherine Zimel, Sophie Shifman, Srusthi Kittane, Fan Wu, Marc Ladanyi, Kevin Ebata, Jennifer Kherani, Barbara J. Brandhuber, James Fagin, Eric J. Sherman, Natasha Rekhtman, Michael F. Berger, Maurizio Scaltriti, David M. Hyman, Barry S. Taylor, Alexander Drilon |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Nature Communications, Vol 13, Iss 1, Pp 1-9 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
2041-1723 |
| DOI: |
10.1038/s41467-022-28848-x |
| Popis: |
The results of the phase 1/2 LIBRETTO-001 clinical trial has recently established the efficacy of the RET inhibitor selpercatinib in RET-driven cancers. Here, the authors characterize the molecular determinants of response and resistance in 72 LIBRETTO-001 lung and thyroid cancer patients treated at a single site. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Full text from SpringerLink